{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:03:27Z","timestamp":1767143007626,"version":"build-2238731810"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T00:00:00Z","timestamp":1656806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T00:00:00Z","timestamp":1656806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We evaluated clinical features and risk factors for mortality in patients with haematological malignancies and COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective, case\u2013control (1:3) study in hospitalized patients with COVID-19. Cases were patients with haematological malignancies and COVID-19, controls had COVID-19 without haematological malignancies. Patients were matched for sex, age and time of hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 66 cases and 198 controls were included in the study. Cases had higher prior corticosteroid use, infection rates, thrombocytopenia and neutropenia and more likely received corticosteroids and antibiotics than controls. Cases had higher respiratory deterioration than controls (78.7% vs 65.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). Notably, 29% of cases developed respiratory worsening\u2009&gt;\u200910\u00a0days after hospital admission, compared to only 5% in controls. Intensive Care Unit admission and mortality were higher in cases than in controls (27% vs 8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002, and 35% vs 10%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                    <jats:p>\n                      At multivariable analysis, having haematological malignancy [OR4.76,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001], chronic corticosteroid therapy [OR3.65,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004], prior infections [OR57.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006], thrombocytopenia [OR3.03,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001] and neutropenia [OR31.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001], low albumin levels [OR3.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001] and\u2009\u2265\u200910\u00a0days from hospital admission to respiratory worsening [OR3.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002] were independently associated with mortality.\n                    <\/jats:p>\n                    <jats:p>\n                      In cases, neutropenia [OR3.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001], prior infections [OR7.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001],\u2009\u2265\u200910\u00a0days to respiratory worsening [OR4.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001], multiple myeloma [OR1.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.044], the variation of the CT lung score during hospitalization [OR2.6,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006] and active treatment [OR 4.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001] all were associated with a worse outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An underlying haematological malignancy was associated with a worse clinical outcome in COVID-19 patients. A prolonged clinical monitoring is needed, since respiratory worsening may occur later during hospitalization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-022-01869-w","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T12:02:11Z","timestamp":1656849731000},"page":"1373-1382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case\u2013control study"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0832-7975","authenticated-orcid":false,"given":"A.","family":"Oliva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Curtolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Volpicelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cancelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Borrazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cogliati Dezza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Marcelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gavaruzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Di Bari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Turriziani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M.","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,3]]},"reference":[{"key":"1869_CR1","unstructured":"WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020, last access on 19 April 2022"},{"key":"1869_CR2","unstructured":"European Centre for Disease Prevention and Control https:\/\/www.ecdc.europa.eu\/en\/covid-19\/latest-evidence\/clinical, last access on 19 April 2022"},{"key":"1869_CR3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/bjh.16956","volume":"190","author":"El-Sharkawi","year":"2020","unstructured":"El-Sharkawi, et al. Haematological cancers and the risk of severe COVID-19: exploration and critical evaluation of the evidence to date. Br J Haematol. 2020;190:336\u201345. https:\/\/doi.org\/10.1111\/bjh.16956 (Epub 2020 Jul 16).","journal-title":"Br J Haematol"},{"key":"1869_CR4","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737\u201345. https:\/\/doi.org\/10.1016\/S2352-3026(20)30251-9 (Epub 2020 Aug 13).","journal-title":"Lancet Haematol"},{"key":"1869_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","volume":"13","author":"J Garc\u00eda-Su\u00e1rez","year":"2020","unstructured":"Garc\u00eda-Su\u00e1rez J, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13:133. https:\/\/doi.org\/10.1186\/s13045-020-00970-7.","journal-title":"J Hematol Oncol"},{"key":"1869_CR6","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1111\/bjh.16863.Epub","volume":"190","author":"S Thibaud","year":"2020","unstructured":"Thibaud S, Tremblay D, Bhalla S, Zimmerman B, Sigel K, Gabrilove J. 2020 Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19. Br J Haematol. 2020;190:e73\u20136. https:\/\/doi.org\/10.1111\/bjh.16863.Epub.","journal-title":"Br J Haematol"},{"key":"1869_CR7","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1182\/blood.2020006288","volume":"135","author":"SP Treon","year":"2020","unstructured":"Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135:1912\u20135. https:\/\/doi.org\/10.1182\/blood.2020006288.","journal-title":"Blood"},{"key":"1869_CR8","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1111\/bjh.16801","volume":"190","author":"F Mart\u00edn-Moro","year":"2020","unstructured":"Mart\u00edn-Moro F, Marquet J, Piris M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190:e16-20. https:\/\/doi.org\/10.1111\/bjh.16801 (Epub 2020 May 27).","journal-title":"Br J Haematol"},{"key":"1869_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","volume":"10","author":"M Dai","year":"2020","unstructured":"Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783\u201391. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0422 (Epub 2020 Apr 28).","journal-title":"Cancer Discov"},{"key":"1869_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00277-020-04328-4","volume":"100","author":"MM R\u00fcthrich","year":"2021","unstructured":"R\u00fcthrich MM, Giessen-Jung C, Borgmann S, et al. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol. 2021;100:383\u201393. https:\/\/doi.org\/10.1007\/s00277-020-04328-4 (Epub 2020 Nov 7).","journal-title":"Ann Hematol"},{"key":"1869_CR11","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","volume":"34","author":"W He","year":"2020","unstructured":"He W, Chen L, Chen Li, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34:1637\u201345. https:\/\/doi.org\/10.1038\/s41375-020-0836-7 (Epub 2020 Apr 24).","journal-title":"Leukemia"},{"key":"1869_CR12","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1007\/s00277-021-04656-z.Epub","volume":"100","author":"R Arcani","year":"2021","unstructured":"Arcani R, Colle J, Cauchois R, et al. 2021 Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue. Ann Hematol. 2021;100:2799\u2013803. https:\/\/doi.org\/10.1007\/s00277-021-04656-z.Epub.","journal-title":"Ann Hematol"},{"key":"1869_CR13","unstructured":"Foc\u00e0, E., Ripamonti, D., Rizzi, M., Bonfanti, P., Bruno, R., Casari, et al, 2020. Vademecum per la gestione terapeutica e di supporto per pazienti con infezioni da coronavirus COVID19. SIMIT SEZIONE REGIONE LOMBARDIA. edizione 3.0, pp. 1\u20139. https:\/\/www.simit.org\/images\/regioni\/lombardia\/comunicazioni\/Vademecum%20COVID-19\/4.%20vademecum%201.0%20%2001.03.20.pdf."},{"key":"1869_CR14","unstructured":"Codeluppi M, Ratti G, Nolli M, Campagna A, Marata AM et al. 2020. PROTOCOLLO TERAPEUTICO per la terapia antivirale dei pazienti con infezione da COVID19. Update 21 marzo 2020. Regione Emilia Romagna, Direzione Generale Cura della Persona, Salute e Welfare; pp. 1-8. http:\/\/www.fimp-pc.it\/wp-content\/uploads\/2020\/03\/CC_PROTOCOLLO-TERAPEUTICOCOVID19-RER-finale1.pdf."},{"key":"1869_CR15","unstructured":"COVID19 Treatment Guidelines aveilable at https:\/\/www.covid19treatmentguidelines.nih.gov\/overview\/clinical-spectrum\/, last access on 19 April 2022"},{"issue":"4","key":"1869_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):56\u201393. https:\/\/doi.org\/10.1093\/cid\/cir073.","journal-title":"Clin Infect Dis"},{"key":"1869_CR17","unstructured":"ESMO guidelines available at https:\/\/www.esmo.org\/guidelines\/haematological-malignancies, last access on 19 April 2022"},{"key":"1869_CR18","doi-asserted-by":"publisher","first-page":"115347","DOI":"10.1016\/j.diagmicrobio.2021.115347","volume":"100","author":"F CogliatiDezza","year":"2021","unstructured":"CogliatiDezza F, Oliva A, Cancelli F, Savelloni G, Valeri S, Mauro V, Calabretto M, Russo G, Venditti M, Turriziani O, Mastroianni CM. Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection. Diagn Microbiol Infect Dis. 2021;100:115347. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115347 (Epub 2021 Feb 12 PMID: 33639375; PMCID: PMC7879029).","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1869_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1148\/radiol.2462070712","volume":"246","author":"DM Hansell","year":"2008","unstructured":"Hansell DM, Bankier AA, MacMahon H, McLoud TC, M\u00fcller NL, Remy J. Fleischner society: glossary of terms for thoracic imaging. Radiology. 2008;246:697\u2013722. https:\/\/doi.org\/10.1148\/radiol.2462070712.","journal-title":"Radiology"},{"key":"1869_CR20","doi-asserted-by":"publisher","first-page":"E55","DOI":"10.1148\/radiol.2020200843","volume":"296","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology. 2020;296:E55-64. https:\/\/doi.org\/10.1148\/radiol.2020200843.","journal-title":"Radiology"},{"key":"1869_CR21","doi-asserted-by":"publisher","first-page":"100775","DOI":"10.1016\/j.blre.2020.100775","volume":"47","author":"QuanQiu Wang","year":"2021","unstructured":"Wang QuanQiu, Berger NA, Rong Xu. When hematologic malignancies meet COVID-19 in the United States: infections, death and disparities. Blood Rev. 2021;47:100775. https:\/\/doi.org\/10.1016\/j.blre.2020.100775 (Epub 2020 Nov 9).","journal-title":"Blood Rev"},{"key":"1869_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/ejh.13493","volume":"105","author":"JM Sanchez-Pina","year":"2020","unstructured":"Sanchez-Pina JM, Rodriguez MR, Quismondo NC, et al. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. Eur J Haematol. 2020;105:597\u2013607. https:\/\/doi.org\/10.1111\/ejh.13493 (Epub 2020 Aug 11).","journal-title":"Eur J Haematol"},{"key":"1869_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","volume":"14","author":"L Pagano","year":"2021","unstructured":"Pagano L, Salmanton-Garc\u00eda J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14:168. https:\/\/doi.org\/10.1186\/s13045-021-01177-0.","journal-title":"J Hematol Oncol"},{"key":"1869_CR24","doi-asserted-by":"publisher","first-page":"8441","DOI":"10.12998\/wjcc.v9.i28.8441","volume":"9","author":"C Ramasamy","year":"2021","unstructured":"Ramasamy C, Mishra AK, John KJ, Lal A. Clinical considerations for critically ill COVID-19 cancer patients: A systematic review. World J Clin Cases. 2021;9:8441\u201352. https:\/\/doi.org\/10.12998\/wjcc.v9.i28.8441.","journal-title":"World J Clin Cases"},{"key":"1869_CR25","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1111\/bjh.16935","volume":"190","author":"V Shah","year":"2020","unstructured":"Shah V, Ko TK, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King\u2019s College Hospital experience. Br J Haematol. 2020;190:e279\u201382. https:\/\/doi.org\/10.1111\/bjh.16935 (Epub 2020 Aug 10).","journal-title":"Br J Haematol"},{"key":"1869_CR26","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1002\/cncr.33160","volume":"126","author":"C Cattaneo","year":"2020","unstructured":"Cattaneo C, Daffini R, Pagani C, et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer. 2020;126:5069\u201376. https:\/\/doi.org\/10.1002\/cncr.33160 (Epub 2020 Sep 10).","journal-title":"Cancer"},{"key":"1869_CR27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ajem.2020.09.056","volume":"45","author":"B Abbasi","year":"2021","unstructured":"Abbasi B, Akhavan R, GhamariKhameneh A, Zandi B, Farrokh D, Pezeshki Rad M, FeyziLaein A, Darvish A, Bijan B. Evaluation of the relationship between inpatient COVID-19 mortality and chest CT severity score. Am J Emerg Med. 2021;45:458\u201363. https:\/\/doi.org\/10.1016\/j.ajem.2020.09.056 (Epub 2020 Sep 28 PMID: 33039235).","journal-title":"Am J Emerg Med"},{"key":"1869_CR28","doi-asserted-by":"publisher","first-page":"6808","DOI":"10.1007\/s00330-020-07033-y","volume":"30","author":"M Francone","year":"2020","unstructured":"Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro L, Panebianco V, Andreoli C, Colaiacomo MC, Zingaropoli MA, Ciardi MR, Mastroianni CM, Pugliese F, Alessandri F, Turriziani O, Ricci P, Catalano C. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020;30:6808\u201317. https:\/\/doi.org\/10.1007\/s00330-020-07033-y (Epub 2020 Jul 4 PMID: 32623505).","journal-title":"Eur Radiol"},{"key":"1869_CR29","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1002\/jmv.26856","volume":"93","author":"L Loffredo","year":"2021","unstructured":"Loffredo L, Campana A, Olivini N, Cotugno N, Palma P, Oliva A, Salvatori G, Zicari AM, Violi F. Hypoalbuminemia and clinical adverse events in children with COVID-19. J Med Virol. 2021;93:2611\u20133. https:\/\/doi.org\/10.1002\/jmv.26856 (Epub 2021 Feb 15 PMID: 33554335).","journal-title":"J Med Virol"},{"key":"1869_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/ars.2020.8142","volume":"35","author":"F Violi","year":"2021","unstructured":"Violi F, Cangemi R, Romiti GF, Ceccarelli G, Oliva A, Alessandri F, Pirro M, Pignatelli P, Lichtner M, Carraro A, Cipollone F, D\u2019ardes D, Pugliese F, Mastroianni CM. Is Albumin Predictor of Mortality in COVID-19? Antioxid Redox Signal. 2021;35:139\u201342. https:\/\/doi.org\/10.1089\/ars.2020.8142 (Epub 2020 Jun 22 PMID: 32524832).","journal-title":"Antioxid Redox Signal"},{"key":"1869_CR31","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCRESAHA.120.317173","volume":"127","author":"F Violi","year":"2020","unstructured":"Violi F, Ceccarelli G, Cangemi R, Alessandri F, D\u2019Ettorre G, Oliva A, Pastori D, Loffredo L, Pignatelli P, Ruberto F, Venditti M, Pugliese F, Mastroianni CM. Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. Circ Res. 2020;127:400\u20131. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317173 (Epub 2020 Jun 8 PMID: 32508261).","journal-title":"Circ Res"},{"key":"1869_CR32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/hon.2925","volume":"39","author":"K Doucette","year":"2021","unstructured":"Doucette K, Percival ME, Williams L, Kandahari A, Taylor A, Wang S, Ahn J, Karp JE, Lai C. Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia. Hematol Oncol. 2021;39:697\u2013706. https:\/\/doi.org\/10.1002\/hon.2925 (Epub 2021 Sep 9 PMID: 34499366).","journal-title":"Hematol Oncol"},{"key":"1869_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04736-0","author":"J Schaffrath","year":"2021","unstructured":"Schaffrath J, Diederichs T, Unverzagt S, Wass M, Gl\u00e4ser U, Weber T, Binder M, M\u00fcller-Tidow C, M\u00fcller LP. Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2021. https:\/\/doi.org\/10.1007\/s00277-021-04736-0.","journal-title":"Ann Hematol"},{"key":"1869_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","volume":"223","author":"JH Baang","year":"2021","unstructured":"Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, Wobus CE, Adams M, Washer L, Martin ET, Lauring AS. Prolonged severe acute respiratory syndrome coronavirus 2 Replication in an immunocompromised patient. J Infect Dis. 2021;223:23\u20137. https:\/\/doi.org\/10.1093\/infdis\/jiaa666.","journal-title":"J Infect Dis"},{"key":"1869_CR35","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/cid\/ciab072","volume":"73","author":"MK Hensley","year":"2021","unstructured":"Hensley MK, Bain WG, Jacobs J, Nambulli S, Parikh U, Cillo A, Staines B, Heaps A, Sobolewski MD, Rennick LJ, et al. Intractable COVID-19 and Prolonged SARS-CoV-2 Replication in a CAR-T-cell Therapy Recipient A Case Study. Clin Infect Dis. 2021;73:812.","journal-title":"Clin Infect Dis"},{"key":"1869_CR36","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","volume":"183","author":"VA Avanzato","year":"2020","unstructured":"Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, Barbian K, Judson SD, Fischer ER, Martens C, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183:1901-12.e9. https:\/\/doi.org\/10.1016\/j.cell.2020.10.049.","journal-title":"Cell"}],"updated-by":[{"DOI":"10.1007\/s15010-022-01892-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000}}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01869-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-022-01869-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01869-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T12:29:08Z","timestamp":1664454548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-022-01869-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,3]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1869"],"URL":"https:\/\/doi.org\/10.1007\/s15010-022-01869-w","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,3]]},"assertion":[{"value":"19 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s15010-022-01892-x","URL":"https:\/\/doi.org\/10.1007\/s15010-022-01892-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the local Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}